Evidence map›Paper›PMID 27730517›Full record

ReviewCurrent diabetes reports2016

Heart Failure: a Major Cardiovascular Complication of Diabetes Mellitus.

Gül Bahtiyar, David Gutterman, Harold Lebovitz

Registry-linked trialOpen access · hybridAbstract readReview
In one paragraph

Review in Current diabetes reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03323216 (BIO-2-HEART Study), which is not on this map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03323216 recruitingnot on this mapstarted 2018, after this paper: background citation

BIO-2-HEART Study (Identifying New BIOmarkers in Patients With Type 2 Diabetes Mellitus and HEArt Failure Receiving Cardiac Resynchronization Therapy Device Implantation)

TypeobservationalSponsorRWTH Aachen UniversityRan2018 to 2026Enrolled400ConditionsHeart Failure, Diabetes Mellitus, Type 2Arms6-minute walk test, Study specific questionnaire, Blood collection
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Association between diabetes and heart failure after coronary artery bypass grafting: Danish register-based cohort study.Clinical research in cardiology : official journal of the German Cardiac Society · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Emerging roles of exosomal miRNAs in diabetes mellitus.Clinical and translational medicine · 2021
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Gül BahtiyarDivision of Endocrinology, State University of New York Health Science Center, Brooklyn, NY, USA.
David GuttermanDivision of Cardiology, Medical College of Wisconsin, Milwaukee, WI, USA.
Harold LebovitzDivision of Endocrinology, State University of New York Health Science Center, Brooklyn, NY, USA. hlebovitz1@hotmail.com.
State University of New York · USMedical College of Wisconsin · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure (HF) is a major cardiovascular complication of diabetes mellitus (DM). The greatest risk factor for HF is age, and data indicate that 6 to 10 % of individuals over the age of 65 years suffer from HF. Patients with DM have a 2.5-fold increased risk for developing HF than individuals without DM. The 25 to 40 % of patients with HF who have DM have worse outcome (death from cardiovascular disease or hospitalization for worsening HF) than patients without DM. Hyperglycemia is a risk factor for the development of HF with an increase in incidence of HF rising from 10 % at hemoglobin A1c (HbA1c) 8.0 to 9.0 % to 71 % at a HbA1c > 10 %. Patients with DM and HF are equally distributed between those with low ejection fractions and those with normal ejection fractions. The HF treatment regimens for patients with HF and DM (blockade of angiotensin II synthesis or action, cardioselective β-adrenergic blockade, mineralocorticoid receptor blockade, and diuretics) are the same as for HF patients without DM, though the benefit on clinical outcomes is not as great. The new angiotensin-neprilysin inhibitors appear to provide increase outcome benefits in both HF patients with or without DM. Glycemic control impacts the clinical outcomes in patients with HF and DM in a U-shaped relationship with poorer survival at low and high mean HbA1c levels. The optimal chronic glycemic control occurs at an HbA1c of 7.5 to 8.0 % for patients with DM who have symptoms of HF.

Indexed as

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsDiabetes ComplicationsGlycated HemoglobinHeart FailureHumansHyperglycemiaRenin InhibitorsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsGlycated Hemoglobinhemoglobin A1c protein, humanRenin InhibitorsCardiovascular complicationsDiabetes mellitusHeart failure

Identifiers

PMID27730517
PMCPMC5059411
OpenAlexW2530741259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.